logo
logo

Wheeler Bio Announces Initial Closing Of Series A Round Supporting New Biologics Drug Substance Gmp Expansion In Oklahoma

Oct 04, 2022•about 3 years ago
Oklahoma CityBiotechnology

Description

Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in small batch clinical production of biologics and GMP-grade reagents using their open-source platform, Portable CMCTM, today announced the first closing of their Series A financing round. The round was co-led by Charles River Laboratories and Echo Investment Capital with participation from ATUM, Floating Point Advisors, Plains Venture Partners (a subsidiary of i2E), and Pine Ridge Ventures.

Company Information

Company

Wheeler Bio

Location

120 ROBERT S. KERR AVE., SUITE 701

Oklahoma City, Oklahoma, United States

About

Wheeler Bio is a contract development and manufacturing pioneer who has established the ModularCMC™ platform that enables the rapid translation of antibody-based therapeutics from discovery to clinical studies while ensuring scalability in support of advanced development and commercialization. ModularCMC streamlines the path between drug discovery and clinical manufacturing through well-defined systematic work packages ultimately resulting in cGMP product supported by a comprehensive Common Technical Document (CTD) Module 3 for Investigational New Drug Applications (INDs). Wheeler's High Science/High Touch approach combines cutting edge development and cGMP manufacturing technologies with a deeply experienced scientific team committed to timeline transparency, scientific rigor and a true partnering mindset. Wheeler Bio's mission is to accelerate the translation of drug discoveries into clinical impact for our partners and the patients they seek to serve. 

Related People

3 contacts

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details